Orsiro Coronary Drug-Eluting Stent Receives Market Approval in Japan

TOKYO, Japan and BUELACH, Switzerland, January 22, 2018 – BIOTRONIK announced today market approval for its Orsiro¹ coronary drug-eluting stent (Orsiro DES) by the Japanese Ministry of Health. This was supported by the positive 12-month outcomes of the BIOFLOW-IV clinical study which were presented at the 81st Japan Circulation Society congress. The BIOFLOW-IV study is a prospective multi-center, international randomized controlled trial with a five-year follow-up.

“We are excited to make this innovative product available to Japanese patients together with Japan Lifeline, our distribution partner for Orsiro,” said Jeffrey Annis, Managing Director of BIOTRONIK Japan.

With its ultrathin 60 micron struts (≦3.0mm in diameter) and unique proBIO coating which reduces nickel ion release, Orsiro has consistently displayed its effectiveness and safety in numerous clinical trials, with more than 32,500 patients around the world enrolled in the Orsiro clinical program to date. Most recently, the BIOFLOW-V trial, published in The Lancet², has shown significantly lower target lesion failure rates for Orsiro when compared to the Xience³ stent family.

“Japan is one of the most important markets in the world, and gaining access to it is a significant milestone for our DES program, as well as for making this innovative product available globally,” commented Dr. Alexander Uhl, Vice President of Marketing at BIOTRONIK Vascular Intervention.

Contact Japan:
Chieko Takekawa
Marketing Communication Manager
BIOTRONIK Japan. Inc.
Ebisu Business Tower 13F, 1-19-19 Ebisu Shibuya-ku
Tokyo, Japan 150-0013
Tel +81 (0) 3 3473 7476
Email: chieko.takekawa@biotronik.com

A global leader in cardio- and endovascular medical technology, BIOTRONIK is headquartered in Berlin, Germany, and represented in over 100 countries. Several million patients have received BIOTRONIK implants designed to save and improve the quality of their lives, or have been treated with BIOTRONIK coronary and peripheral vascular intervention products. Since its development of the first German pacemaker in 1963, BIOTRONIK has engineered many innovations, including Magmaris⁴, the first clinically-proven resorbable magnesium scaffold; BIOTRONIK Home Monitoring^®; Pulsar, the world’s first 4 F compatible stent for treating long lesions; Orsiro, the industry’s first hybrid drug-eluting stent; and the world’s first implantable cardioverter defibrillators and heart failure therapy devices with ProMRI^® technology.

www.orsiro.com

@BIOTRONIK_News

www.linkedin.com/company/biotronik

1CAUTION – Investigational device in the United States. Limited by US law to investigational use.

2Kandzari D et al., Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents versus Thin Durable Polymer Everolimus-Eluting Stents in Patients Undergoing Coronary Revascularisation (BIOFLOW-V): a randomized trial, 2017, The Lancet. 2017

3Xience is a registered trademark of Abbott Cardiovascular Systems Inc.

4Not currently available in the United States.

Global Public Relations

+49 (0) 30 68905 1414
press@biotronik.com